Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Imaging of Solid Tumors Using DLL3 SPECT

NCT07052760 is registered in ClinicalTrials.gov with Thomas Hope as lead sponsor.

NCT NCT07052760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07052760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Imaging of Solid Tumors Using DLL3 SPECT
Lead sponsor
Thomas Hope
Phase
Phase 1
Overall status
Withdrawn
Start date
April 30, 2026
Completion date
May 31, 2028
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

castration resistant prostate cancer, castration resistant prostate cancer (crpc), neuroendocrine (ne) tumors, solid tumor cancer